Latest Lymphoid leukemia Stories
The leukemia therapeutics market report gives the detailed analysis on the major market drivers, restraints, and opportunities in North America, & Europe.
- Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions EAST HANOVER, N.J., Dec.
Additional test for susceptibility in certain types of lymphoma FT. MYERS, Fla., Oct. 23, 2014 /PRNewswire/ -- NeoGenomics, Inc.
Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options THOUSAND OAKS,
FDA Submission Reinforces Commitment to Addressing Significant Unmet Needs for Patients With Acute Lymphoblastic Leukemia, an Aggressive Cancer With Limited Treatment Options THOUSAND
Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced
The acute lymphoblastic leukemia therapeutics market is segmented based on the existing regimens and drugs, pipeline drugs, and geography;
DUBLIN, April 23, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/3mgfnj/acute) has announced the addition of the "Acute Lymphocytic/Lymphoblastic
LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
Acute Lymphocytic Leukemia Therapeutics Market report categorizes the market in G8 countries into the following segments by Drug and by Geography.